Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML

AKSU S., Bektas Ö., Uz B., BÜYÜKAŞIK Y., SAYINALP N., Ozcebe O., ...Daha Fazla

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, cilt.22, sa.1, ss.1-7, 2012 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 1
  • Basım Tarihi: 2012
  • Doi Numarası: 10.4999/uhod.12003
  • Dergi Adı: UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1-7
  • Anahtar Kelimeler: Dasatinib, First-line therapy, Chronic myeloid leukemia, Pleural effusion, CHRONIC MYELOID-LEUKEMIA, CHROMOSOME-POSITIVE LEUKEMIA, CHRONIC-PHASE, BCR-ABL, CYTOGENETIC RESPONSES, IMATINIB MESYLATE, THERAPY, RESISTANT, INHIBITION
  • Karadeniz Teknik Üniversitesi Adresli: Hayır

Özet

Dasatinib is considered an effective treatment agent in imatinib-resistant and newly diagnosed chronic phase CML patients. Patients receiving dasatinib 100 mg once daily regime suffered significantly fewer thrombocytopenia and pleural effusion events than those receving 70 mg twice daily. Effective molecular monitoring and the proper management of pleural effusion during the first-line dasatinib administration in CML are essential. Pleural effusion may develop any time of the treatment and is easily managed by treatment interruption, dose reduction and supportive therapy. In this article, we intended to assess the rational of managing CML and pleural effusion that successfully managed with dose reduction and supportive care.